Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: Suite 1080, 789 West Pender Street
Tel: N/A
IR: See website
Key People
Mariusz Olejniczak
Chief Executive Officer
Michael Malana
Chief Financial Officer
Liam Lake Corcoran
Canadian Vice President of Legal, Corporate Secretary, Director
Business Overview
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
Financial Overview
For the nine months ended 30 September 2021, WPD Pharmaceuticals Inc revenues was not reported. Net loss decreased 46% to C$3.1M. Lower net loss reflects Share-based payments decrease of 96% to C$138K (expense), Other income increase from C$795K to C$1.7M (income), Marketing and advertising decrease of 81% to C$70K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.05 to -C$0.03.
Reporting Currency: Canadian Dollars
Enterprise value: $3.81M as of Sep 30, 2021
Annual revenue (TTM): $0.00M as of Sep 30, 2021
EBITDA (TTM): -$6.13M as of Sep 30, 2021
Net annual income (TTM): -$4.86M as of Sep 30, 2021
Free cash flow (TTM): -$1.37M as of Sep 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 113,438,244 as of Sep 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization